Literature DB >> 20431030

Macrophage inhibitory cytokine-1 regulates melanoma vascular development.

Sung Jin Huh1, Chin-Ying Chung, Arati Sharma, Gavin P Robertson.   

Abstract

Expression of macrophage inhibitory cytokine-1 (MIC-1), a member of the transforming growth factor-beta family, normally increases during inflammation or organ injury. MIC-1 is also expressed at higher levels in melanomas; however, its role in tumorigenesis is unknown. This report identifies a novel function for MIC-1 in cancer. MIC-1 was overexpressed in approximately 67% of advanced melanomas, accompanied by fivefold to six-fold higher levels of secreted protein in serum of melanoma patients compared with normal individuals. Constitutively active mutant (V600E)B-Raf in melanoma regulated downstream MIC-1 expression. Indeed, small-interfering RNA-mediated targeting of MIC-1 or (V600E)B-Raf reduced expression and secretion by three-fold to fivefold. This decrease in MIC-1 levels reduced melanoma tumorigenesis by approximately threefold, but did not alter cultured cell growth, suggesting a unique function other than growth control. Instead, inhibition of MIC-1 was found to mechanistically retard melanoma tumor vascular development, subsequently affecting tumor cell proliferation and apoptosis. This role in melanoma angiogenesis was confirmed by comparing MIC-1 and vascular endothelial growth factor (VEGF) function in chick chorioallantoic membrane and matrigel plug assays. Similar to VEGF in melanomas, MIC-1 stimulated directional vessel development, acting as a potent angiogenic factor. Thus, MIC-1 is secreted from melanoma cells together with VEGF to promote vascular development mediated by (V600E)B-Raf signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431030      PMCID: PMC2877855          DOI: 10.2353/ajpath.2010.090963

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Authors:  Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta
Journal:  BMC Med Genomics       Date:  2008-04-28       Impact factor: 3.063

2.  Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Authors:  P X Li; J Wong; A Ayed; D Ngo; A M Brade; C Arrowsmith; R C Austin; H J Klamut
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

3.  Secreted and cell surface genes expressed in benign and malignant colorectal tumors.

Authors:  P Buckhaults; C Rago; B St Croix; K E Romans; S Saha; L Zhang; B Vogelstein; K W Kinzler
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 4.  Friends or foes - bipolar effects of the tumour stroma in cancer.

Authors:  Margareta M Mueller; Norbert E Fusenig
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

5.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 6.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma.

Authors:  David A Brown; Robyn L Ward; Philip Buckhaults; Tao Liu; Katharine E Romans; Nicholas J Hawkins; Asne R Bauskin; Kenneth W Kinzler; Bert Vogelstein; Samuel N Breit
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

8.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing.

Authors:  Jens Harborth; Sayda M Elbashir; Kim Vandenburgh; Heiko Manninga; Stephen A Scaringe; Klaus Weber; Thomas Tuschl
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003-04

9.  Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.

Authors:  Kwang-Kyu Kim; Jung Joon Lee; Young Yang; Kwan-Hee You; Jeong-Hyung Lee
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

10.  Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.

Authors:  Dong Hoon Lee; Young Yang; Soon Jung Lee; Kun-Yong Kim; Tae Hyeon Koo; Sun Mi Shin; Kyu Sang Song; Young Ho Lee; Yung-Jin Kim; Jung Joon Lee; Inpyo Choi; Jeong-Hyung Lee
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  18 in total

1.  Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2012-03-10

2.  Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.

Authors:  Arati Sharma; SubbaRao V Madhunapantula; Raghavendra Gowda; Arthur Berg; Rogerio I Neves; Gavin P Robertson
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

3.  GDF-15 in Pulmonary and Critical Care Medicine.

Authors:  Fien M Verhamme; Christine M Freeman; Guy G Brusselle; Ken R Bracke; Jeffrey L Curtis
Journal:  Am J Respir Cell Mol Biol       Date:  2019-06       Impact factor: 6.914

4.  Early assessment of cancer outcomes in New York City firefighters after the 9/11 attacks: an observational cohort study.

Authors:  Rachel Zeig-Owens; Mayris P Webber; Charles B Hall; Theresa Schwartz; Nadia Jaber; Jessica Weakley; Thomas E Rohan; Hillel W Cohen; Olga Derman; Thomas K Aldrich; Kerry Kelly; David J Prezant
Journal:  Lancet       Date:  2011-09-03       Impact factor: 79.321

Review 5.  Concise review: growth differentiation factor 15 in pathology: a clinical role?

Authors:  Jill Corre; Benjamin Hébraud; Philippe Bourin
Journal:  Stem Cells Transl Med       Date:  2013-11-04       Impact factor: 6.940

Review 6.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.

Authors:  Yuhua Wang; Zhenghong Xu; Shutao Guo; Lu Zhang; Arati Sharma; Gavin P Robertson; Leaf Huang
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

8.  GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells.

Authors:  Nils Nickel; Danny Jonigk; Tibor Kempf; Clemens L Bockmeyer; Lavinia Maegel; Johanna Rische; Florian Laenger; Ulrich Lehmann; Clemens Sauer; Mark Greer; Tobias Welte; Marius M Hoeper; Heiko A Golpon
Journal:  Respir Res       Date:  2011-05-06

9.  Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Authors:  Xiao-Bing Wang; Xing-Ran Jiang; Xi-Ying Yu; Lin Wang; Shun He; Fei-Yue Feng; Li-Ping Guo; Wei Jiang; Shih-Hsin Lu
Journal:  Cancer Sci       Date:  2014-01-02       Impact factor: 6.716

10.  Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.

Authors:  M Mimeault; S L Johansson; S K Batra
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.